NEXT Oncology
NEXT Oncology is a leading Phase 1 cancer research center dedicated to transforming patient care by advancing the next breakthrough medicines in cancer research. They strive to provide exceptional care, the newest cancer treatments, and a community dedicated to finding a cure. With multiple locations worldwide, they are committed to innovative clinical trials and advancing cancer treatment through research.
Industries
Nr. of Employees
small (1-50)
NEXT Oncology
Services
End-to-end conduct of Phase I oncology trials including patient screening, enrollment, investigational agent administration, safety monitoring, and dose-escalation cohorts.
On-site pharmacy services for preparation, compounding and secure storage of hazardous and investigational oncology agents.
Clinical specimen collection, on-site processing and coordination of sample shipment for study-specific testing.
Services to open and manage clinical trial sites, coordinate multi-location enrollment and support sponsor/CRO operational needs.
Study documentation, regulatory recordkeeping, and data management practices aligned with FDA expectations for early-phase trials.
Patient-facing communication channels including a digital patient portal to support study logistics and participant contact.
End-to-end conduct of Phase I oncology trials including patient screening, enrollment, investigational agent administration, safety monitoring, and dose-escalation cohorts.
On-site pharmacy services for preparation, compounding and secure storage of hazardous and investigational oncology agents.
Clinical specimen collection, on-site processing and coordination of sample shipment for study-specific testing.
Services to open and manage clinical trial sites, coordinate multi-location enrollment and support sponsor/CRO operational needs.
Study documentation, regulatory recordkeeping, and data management practices aligned with FDA expectations for early-phase trials.
Patient-facing communication channels including a digital patient portal to support study logistics and participant contact.
Expertise Areas
- Phase I clinical trial management
- Oncology clinical pharmacology
- First-in-human and dose-escalation studies
- Clinical operations and infusion services
Key Technologies
- Antibody-drug conjugates (ADC)
- CAR T-cell therapy
- Natural killer (NK) cell therapy
- Monoclonal antibody therapeutics
News & Updates
Dr. Alexander I. Spira has been appointed as the new Chief Scientific Officer at NEXT Oncology, focusing on advancing Phase 1 oncology trials.
NEXT Oncology has expanded its facilities by opening a new Phase 1 clinical trial center in Houston, Texas, as part of its global growth plans.
Investigators from NEXT Oncology presented 25 abstracts, posters, and presentations at the ASCO 2022 meeting, highlighting ongoing Phase 1 clinical trials.
Dr. Spira provided an overview of the use of adagrasib in advanced KRAS G12C-mutant non-small cell lung cancer during the ASCO 2022 meeting.
Dr. Spira was appointed as the new Chief Scientific Officer at NEXT Oncology, leading scientific and research strategy.
NEXT Oncology opened its seventh cancer care center in Houston, Texas, as part of its global growth initiative.
Dr. Alexander I. Spira has been appointed as the new Chief Scientific Officer at NEXT Oncology, focusing on advancing Phase 1 oncology trials.
NEXT Oncology has expanded its facilities by opening a new Phase 1 clinical trial center in Houston, Texas, as part of its global growth plans.
Investigators from NEXT Oncology presented 25 abstracts, posters, and presentations at the ASCO 2022 meeting, highlighting ongoing Phase 1 clinical trials.
Dr. Spira provided an overview of the use of adagrasib in advanced KRAS G12C-mutant non-small cell lung cancer during the ASCO 2022 meeting.
Dr. Spira was appointed as the new Chief Scientific Officer at NEXT Oncology, leading scientific and research strategy.
NEXT Oncology opened its seventh cancer care center in Houston, Texas, as part of its global growth initiative.